Catalog No.:AA001JSI

1446261-44-4 | Pamiparib

Name: Name:Pamiparib
Brand: AABLOCKS
SKU: AA001JSI
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

5mg

≥98%

in stock

$139.00 $97.00

- +

10mg

≥98%

in stock

$250.00 $175.00

- +

25mg

≥98%

in stock

$413.00 $289.00

- +

50mg

≥98%

in stock

$758.00 $530.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA001JSI

Chemical Name:

Pamiparib

CAS Number:

1446261-44-4

Molecular Formula:

C16H15FN4O

Molecular Weight:

298.3149

MDL Number:

MFCD30489383

SMILES:

Fc1cc2[nH]c3c4c2c(c1)c(=O)[nH]nc4CN1[C@]3(C)CCC1

Properties

Computed Properties

Complexity:

566

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

XLogP3:

1.6

Downstream Synthesis Route

1342063-52-8

1446261-44-4

[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1

[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1

[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A

[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B

[5]Wang,Hexiang;Ren,Bo;Liu,Ye;Jiang,Beibei;Guo,Yin;Wei,Min;Luo,Lusong;Kuang,Xianzhao;Qiu,Ming;Lv,Lei;Xu,Hong;Qi,Ruipeng;Yan,Huibin;Xu,Dexu;Wang,Zhiwei;Huo,Chang-Xin;Zhu,Yutong;Zhao,Yuan;Wu,Yiyuan;Qin,Zhen;Su,Dan;Tang,Tristin;Wang,Fan;Sun,Xuebing;Feng,Yingcai;Peng,Hao;Wang,Xing;Gao,Yajuan;Liu,Yong;Gong,Wenfeng;Yu,Fenglong;Liu,Xuesong;Wang,Lai;Zhou,Changyou[JournalofMedicinalChemistry,2020,vol.63,#24,p.15541-15563]

1446261-56-8

1446261-44-4

[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1

[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1

[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A

[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B

1446261-57-9

1446261-44-4

[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1

[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1

[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A

[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B

1446261-58-0

1446261-44-4

[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1

[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1

[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A

[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B

1446261-59-1

1446261-44-4

[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1

[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1

[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A

[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B

Literature

Title: Changyou Zhou, et al. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors. WO 2013097225 A1.

Title: Friedlander M, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20(9):1306-1315.

Title: Zhiyu Tang, et al. Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models. Cancer Research. August 2015, Volume 75, Issue 15.

Title: Shiv K. Gupta, et al. Abstract 3505: Inhibition of PARP activity by BGB-290 potentiates efficacy of NSC 362856 in patient derived xenografts of glioblastoma multiforme. Cancer Research. August 2015, Volume 75, Issue 15

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS